- Home
- NEOV vs ATRA Comparison
NEOV vs ATRA Comparison
Compare NEOV & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEOV | ATRA |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.7M | 81.2M |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NEOV | ATRA |
|---|---|---|
| Price | $3.61 | $9.57 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 1.8M | 50.8K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 122.52 |
| EPS | ★ N/A | N/A |
| Revenue | $8,426,835.00 | ★ $120,772,000.00 |
| Revenue This Year | $150.56 | N/A |
| Revenue Next Year | $5.31 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 218.59 | N/A |
| 52 Week Low | $1.36 | $3.92 |
| 52 Week High | $7.13 | $19.15 |
Technical Indicators
Market Signals| Indicator | NEOV | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 56.86 | 54.82 |
| Support Level | $3.40 | $8.98 |
| Resistance Level | $3.85 | $10.02 |
| Average True Range (ATR) | 0.31 | 0.53 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 51.17 | 34.39 |
Price Performance
Historical ComparisonAbout NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.